Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Sanjal H Desai, Levi D. Pederson, Betsy Laplant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2508.

https://doi.org/10.1182/blood-2021-151276

Published: 2021

Journal Articles

Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas

Robert M. Kraft, MD, Melissa C. Larson, MS, Kathleen J. Yost, PhD, Thomas M. Habermann, MD, Matthew J. Maurer, MS, William R. Macon, MD, Umar Farooq, MD, David J. Inwards, MD, Gita Thanarajasingam, MD, Brian K. Link, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134897

Published: 2020

Journal Articles

Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E

Sanjal H Desai, MD, Betsy Laplant, MS, William R. Macon, MD, Rebecca L. King, MD, Yucai Wang, MDPhD, David J. Inwards, MD, Ivana Micallef, MD, Patrick B. Johnston, Luis F. Porrata, MD, Stephen M. Ansell, MD PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-141298

Published: 2020

Journal Articles

Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis

Arushi Khurana, MBBS, Raphael Mwangi, Stephen M. Ansell, MD PhD, Thomas M. Habermann, MD, James R. Cerhan, MD PhD, Christopher Strouse, MD, Brian K. Link, MD, Yucai Wang, MDPhD, Rebecca L. King, MD, William R. Macon, MD, Jose C Villasboas, MD, Thomas E. Witzig, MD, Matthew J. Maurer, MS, Grzegorz S. Nowakowski, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141011

Published: 2020

Journal Articles

Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways

Blood (2019) 134 (Supplement_1): 1480.

https://doi.org/10.1182/blood-2019-126860

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Matthew J. Maurer, MS, Umar Farooq, MD, Madison M Wahlen, Thomas M. Habermann, MD, Gita Thanarajasingam, MD, Sergei Syrbu, MD PhD, William R. Macon, MD, Patrick Johnston, MD, Ivana Micallef, MD, Luis Porrata, MD, Susan L. Slager, PhD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Brian K. Link, MD

Blood (2018) 132 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2018-99-114331

Published: 2018

Journal Articles

Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)

Thomas M. Habermann, MD, Angelo Fama, MD, Kay M. Ristow, BS, Matthew J. Maurer, MS, William R. Macon, MD, Stephen M. Ansell, MD PhD, Nabila Nora Bennani, MD, Yogish C Kudva, MBBS, Randall C. Walker, MD, Kimberly D. Watt, Thomas R. Schwab, MD, James R. Cerhan, MD PhD, Rebecca L King, MD

Blood (2018) 132 (Supplement 1): 456.

https://doi.org/10.1182/blood-2018-99-113667

Published: 2018

Journal Articles

Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

Alessia Castellino, MD, Jose Pulido, PhD, Patrick Johnston, Kay M. Ristow, BS, Nabila Nora Bennani, MD, David J Inwards, MD, William R. Macon, MD, Ivana N Micallef, MD, Rebecca L King, MD, Diva Salomao, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Grzegorz Nowakowski, MD

Blood (2018) 132 (Supplement 1): 574.

https://doi.org/10.1182/blood-2018-99-113826

Published: 2018

Journal Articles

An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation

Thomas M. Habermann, MD, Ruth A Lentz, R.N., John J Schmitz, MD, Alexander G von Bormann, BA, Jason Young, MD, Christopher H Hunt, MD, Grzegorz S. Nowakowski, MD, Kristen McCullough, PharmD, Pedro Horna, MD, Adam J Wood, MD, William R. Macon, MD, Paul J Kurtin, MD, Scott L Stafford, MD, Usha Sree Chamarthy, MD, Faraz Khan, MD, Stephen M. Ansell, MD PhD, Rebecca L King, MD

Blood (2018) 132 (Supplement 1): 2247.

https://doi.org/10.1182/blood-2018-99-112887

Published: 2018

Journal Articles

Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder

Angelo Fama, MD, Rebecca L King, MD, Matthew J. Maurer, MS, Kay M. Ristow, BS, William R Macon, MD, Stephen M Ansell, MD, Nora N Bennani, MD, Randall C. Walker, MD, Yogish C Kudva, MBBS, Kymberly D Watt, MD, Thomas R. Schwab, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD, Thomas M. Habermann, MD

Blood (2018) 132 (Supplement 1): 2979.

https://doi.org/10.1182/blood-2018-99-116738

Published: 2018

Journal Articles

High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials

Alessia Castellino, MD, Annalisa Chiappella, MD, Betsy Laplant, MS, Levy D. Pederson, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, William R Macon, MD, Alessandra Tucci, Rebecca L King, MD, Angela Giovanna Congiu, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Umberto Vitolo, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 2962.

https://doi.org/10.1182/blood-2018-99-119495

Published: 2018

Journal Articles

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

David W. Scott, Rebecca L. King, Annette M. Staiger, Susana Ben-Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W. Slack, Daisuke Ennishi, Norbert Schmitz, Michael Pfreundschuh, Grzegorz S. Nowakowski, Brad S. Kahl, Joseph M. Connors, Randy D. Gascoyne, German Ott, William R. Macon, Andreas Rosenwald

Blood (2018) 131 (18): 2060–2064.

https://doi.org/10.1182/blood-2017-12-820605

Published: 2018

Includes: Supplemental data

Journal Articles

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Blood (2017) 130 (Supplement 1): 4115.

https://doi.org/10.1182/blood.V130.Suppl_1.4115.4115

Published: 2017

Journal Articles

Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements"

Ellen D. McPhail, MD, Matthew J Maurer, MS, Rhett P. Ketterling, MD, William R. Macon, MD, Andrew L Feldman, MD, Paul J Kurtin, MD, Thomas E. Witzig, MD, Rakhee Vaidya, MD, Thomas M. Habermann, MD

Blood (2016) 128 (22): 1750.

https://doi.org/10.1182/blood.V128.22.1750.1750

Published: 2016

Journal Articles

Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas)

Thomas M. Habermann, MD, William R. Macon, MD, Matthew J Maurer, MS, Rhett P. Ketterling, MD, Paul J Kurtin, MD, Andrew L Feldman, MD, Rakhee Vaidya, MD, James R Cerhan, MD PhD, Stephen Ansell, MD PhD, Luis Porrata, MD, Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD, Ellen D. McPhail, MD

Blood (2016) 128 (22): 155.

https://doi.org/10.1182/blood.V128.22.155.155

Published: 2016

Journal Articles

Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma

Sean I. Tracy, MD PhD, Matthew J Maurer, MS, Thomas E. Witzig, MD, Matthew T. Drake, MD PhD, Stephen Ansell, MD PhD, Grzegorz S. Nowakowski, MD, David James Inwards, MD, Carrie A Thompson, MD, Patrick B. Johnston, MD PhD, Ivana Micallef, MD, Cristine Allmer, BS, William R. Macon, MD, George J Weiner, MD, Susan L. Slager, PhD, Thomas M. Habermann, MD, Brian K Link, MD, James R Cerhan, MD PhD

Blood (2016) 128 (22): 1104.

https://doi.org/10.1182/blood.V128.22.1104.1104

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Ayed O. Ayed, MD, Levi Pederson, William R. Macon, MD, Betsy R. Laplant, MS, Craig B. Reeder, MD, James M. Foran, MD, Garth Nelson, Candido E. Rivera, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2016) 128 (22): 5322.

https://doi.org/10.1182/blood.V128.22.5322.5322

Published: 2016

Journal Articles

Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL

Jie Qu, MD, Matthew J Maurer, MS, James R Cerhan, MD PhD, Anne J. Novak, PhD, Thomas M. Habermann, MD, William R. Macon, MD, Andrew L Feldman, MD, Thomas E. Witzig, MD, Carrie A Thompson, MD, Sergei Syrbu, MD, Brian K Link, MD, Umar Farooq, MD, Stephen Ansell, MD PhD

Blood (2016) 128 (22): 5299.

https://doi.org/10.1182/blood.V128.22.5299.5299

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Ayed O. Ayed, MD, Annalisa Chiappella, MD, Grzegorz S. Nowakowski, MD, Federica Cavallo, MD, Angela Giovanna Congiu, MD, Gianluca Gaidano, MD PhD, Levi Pederson, Betsy R. Laplant, MS, William R. Macon, MD, Gerardo Musuraca, MD, Alessandro Re, MD, Michele Spina, Thomas E. Witzig, MD, Umberto Vitolo

Blood (2016) 128 (22): 3033.

https://doi.org/10.1182/blood.V128.22.3033.3033

Published: 2016

NARROW

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas

Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E

Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis

Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)

Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation

Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder

High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements"

Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas)

Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only